Atyr PHARMA (NASDAQ:ATYR - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05, Zacks reports.
Atyr PHARMA Stock Down 0.5 %
Shares of Atyr PHARMA stock traded down $0.02 during trading on Friday, reaching $3.97. The company's stock had a trading volume of 2,401,773 shares, compared to its average volume of 1,313,086. The company has a 50-day simple moving average of $3.65 and a two-hundred day simple moving average of $3.07. Atyr PHARMA has a 1-year low of $1.42 and a 1-year high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a market cap of $333.25 million, a price-to-earnings ratio of -4.22 and a beta of 0.98.
Analyst Ratings Changes
A number of research analysts have recently issued reports on ATYR shares. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Friday. Cantor Fitzgerald started coverage on Atyr PHARMA in a report on Monday, January 6th. They issued an "overweight" rating on the stock. Leerink Partners initiated coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price target on the stock. Finally, Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Atyr PHARMA presently has an average rating of "Buy" and an average price target of $18.60.
Read Our Latest Stock Report on ATYR
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
